

# **Product** Data Sheet

### **BEBT-908**

 $\begin{array}{lll} \textbf{Cat. No.:} & HY\text{-}19763 \\ \\ \textbf{CAS No.:} & 1235449\text{-}52\text{-}1 \\ \\ \textbf{Molecular Formula:} & C_{23}H_{25}N_9O_3S \\ \end{array}$ 

Molecular Weight: 507.57

Target: PI3K

Pathway: PI3K/Akt/mTOR

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO : ≥ 37 mg/mL (72.90 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9702 mL	9.8509 mL	19.7017 mL
	5 mM	0.3940 mL	1.9702 mL	3.9403 mL
	10 mM	0.1970 mL	0.9851 mL	1.9702 mL

Please refer to the solubility information to select the appropriate solvent.

## **BIOLOGICAL ACTIVITY**

**Description**BEBT-908 (PI3Kα inhibitor 1) is a selective PI3Kα inhibitor extracted from patent US/20120088764A1, Compound 243, has an

 $IC_{50}$ <0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM $\leq$ IC $_{50}$  $\leq$ 1 μM).

IC<sub>50</sub> & Target PI3Kα HDAC

 $0.1 \,\mu\text{M} \,(\text{IC}_{50})$   $0.1 \,\mu\text{M} \,(\text{IC}_{50})$ 

#### **REFERENCES**

[1]. Cai Xiong, et al. Deazapurines, thienopyrimidines and furopyrimidines as phosphoinositide 3-kinase inhibitors with a zinc binding moiety and their preparation and use in the treatment of diseases. From U.S. Pat. Appl. Publ. (2012), US 20120088764 A1 20120

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$ 

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com